Ashfield Capital Partners LLC lowered its stake in shares of Thermo Fisher Scientific Inc (NYSE:TMO) by 4.1% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 45,256 shares of the medical research company’s stock after selling 1,934 shares during the quarter. Thermo Fisher Scientific comprises about 1.1% of Ashfield Capital Partners LLC’s holdings, making the stock its 25th largest position. Ashfield Capital Partners LLC’s holdings in Thermo Fisher Scientific were worth $8,562,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds and other institutional investors also recently bought and sold shares of TMO. Amalgamated Bank increased its position in Thermo Fisher Scientific by 57.0% during the 2nd quarter. Amalgamated Bank now owns 44,921 shares of the medical research company’s stock worth $7,837,000 after purchasing an additional 16,308 shares in the last quarter. Mutual of America Capital Management LLC increased its position in Thermo Fisher Scientific by 2.1% during the 2nd quarter. Mutual of America Capital Management LLC now owns 47,728 shares of the medical research company’s stock worth $8,327,000 after purchasing an additional 977 shares in the last quarter. Mitchell Capital Management Co. increased its position in Thermo Fisher Scientific by 40.3% during the 2nd quarter. Mitchell Capital Management Co. now owns 44,940 shares of the medical research company’s stock worth $7,841,000 after purchasing an additional 12,910 shares in the last quarter. State Board of Administration of Florida Retirement System increased its position in Thermo Fisher Scientific by 0.9% during the 2nd quarter. State Board of Administration of Florida Retirement System now owns 580,712 shares of the medical research company’s stock worth $101,317,000 after purchasing an additional 5,213 shares in the last quarter. Finally, San Francisco Sentry Investment Group CA acquired a new stake in Thermo Fisher Scientific during the 2nd quarter worth approximately $1,451,000. 86.16% of the stock is owned by institutional investors.
In related news, CEO Marc N. Casper sold 50,000 shares of the firm’s stock in a transaction on Wednesday, November 15th. The stock was sold at an average price of $188.39, for a total transaction of $9,419,500.00. Following the transaction, the chief executive officer now directly owns 252,577 shares in the company, valued at $47,582,981.03. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.49% of the company’s stock.
A number of analysts recently issued reports on TMO shares. Zacks Investment Research raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $208.00 target price for the company in a research report on Thursday, September 7th. Morgan Stanley reaffirmed an “overweight” rating and issued a $220.00 price objective on shares of Thermo Fisher Scientific in a research report on Wednesday, September 6th. Cowen reaffirmed an “outperform” rating and issued a $220.00 price objective (up previously from $200.00) on shares of Thermo Fisher Scientific in a research report on Sunday, September 10th. Leerink Swann reaffirmed a “buy” rating on shares of Thermo Fisher Scientific in a research report on Monday, October 30th. Finally, Deutsche Bank set a $226.00 price objective on shares of Thermo Fisher Scientific and gave the company a “buy” rating in a research report on Thursday, October 26th. One equities research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $205.21.
Thermo Fisher Scientific Inc (TMO) traded up $1.42 during trading on Thursday, hitting $183.87. The stock had a trading volume of 2,262,900 shares, compared to its average volume of 1,561,349. The stock has a market cap of $73,161.61, a PE ratio of 20.05, a P/E/G ratio of 1.67 and a beta of 1.06. The company has a debt-to-equity ratio of 0.85, a quick ratio of 0.81 and a current ratio of 1.26. Thermo Fisher Scientific Inc has a 12 month low of $139.88 and a 12 month high of $201.20.
Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, October 25th. The medical research company reported $2.31 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.24 by $0.07. The company had revenue of $5.12 billion during the quarter, compared to analysts’ expectations of $5.03 billion. Thermo Fisher Scientific had a return on equity of 15.94% and a net margin of 11.73%. The business’s revenue was up 13.9% on a year-over-year basis. During the same period in the prior year, the business posted $2.03 EPS. equities analysts forecast that Thermo Fisher Scientific Inc will post 9.36 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Monday, January 15th. Investors of record on Friday, December 15th will be paid a dividend of $0.15 per share. This represents a $0.60 annualized dividend and a yield of 0.33%. The ex-dividend date is Thursday, December 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.19%.
ILLEGAL ACTIVITY WARNING: “Thermo Fisher Scientific Inc (TMO) Shares Sold by Ashfield Capital Partners LLC” was first posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.thelincolnianonline.com/2017/12/07/thermo-fisher-scientific-inc-tmo-shares-sold-by-ashfield-capital-partners-llc.html.
Thermo Fisher Scientific Profile
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc (NYSE:TMO).
Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.